4//SEC Filing
Shukla Sath 4
Accession 0000950170-24-011487
CIK 0001701108other
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 8:40 PM ET
Size
8.8 KB
Accession
0000950170-24-011487
Insider Transaction Report
Form 4
Shukla Sath
CEO & President
Transactions
- Sale
Common Stock
2024-02-05$1.45/sh−45,093$65,385→ 1,176,007 total - Award
Common Stock
2024-02-01+679,501→ 1,252,001 total - Sale
Common Stock
2024-02-02$1.37/sh−30,901$42,334→ 1,221,100 total
Footnotes (4)
- [F1]Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2025, subject to the Reporting Person's continued service through the applicable vesting date.
- [F2]The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2022 and February 1, 2023 pursuant to a "sell to cover" provision included in each RSU Agreement.
- [F3]Represents the weighted average sales price per share. The shares sold at prices ranging from $1.36 to $1.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F4]The reported transaction is a sale of common stock pursuant to a preexisting 10b5-1 plan upon the vesting of RSUs that were granted to the Reporting Person on February 1, 2022 and February 1, 2023.
Documents
Issuer
Spero Therapeutics, Inc.
CIK 0001701108
Entity typeother
Related Parties
1- filerCIK 0001782817
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 8:40 PM ET
- Size
- 8.8 KB